Research programme: anticancer natural human antibodies - Patrys

Drug Profile

Research programme: anticancer natural human antibodies - Patrys

Alternative Names: 3E10; 5C6; Deoxymab; PAT-BA1; PAT-BA2; PAT-BA4; PAT-CM1; PAT-DX1; PAT-NM1; PAT-NM2; PAT-PM1; PAT-PM2; PAT-SM3; PAT-SM4; PAT-SM5

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OncoMab GmbH; Patrys; Yale University
  • Developer Patrys
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; DNA repair inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Aug 2017 Patrys has patent protection for Deoxymab 3E10 technology, including lead candidate PAT DX1 in USA
  • 13 Jun 2017 Patrys licensed worldwide rights of Deoxymab 3E10 technology from Yale University
  • 13 Sep 2016 Patrys plans preclinical trials in Cancer in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top